Nanoform Finland Oyj (NANOFH.HE)
EUR 1.29
(2.7%)
EUR 1.29
(2.7%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.56 Million EUR | -26.41% |
| 2022 | 3.48 Million EUR | 78.42% |
| 2021 | 1.95 Million EUR | 184.61% |
| 2020 | 686.74 Thousand EUR | 1298.87% |
| 2019 | 49.09 Thousand EUR | -79.11% |
| 2018 | 235 Thousand EUR | 261.54% |
| 2017 | 65 Thousand EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 602 Thousand EUR | 50.32% |
| 2024 Q2 | 651 Thousand EUR | 8.14% |
| 2023 Q3 | 641 Thousand EUR | -17.82% |
| 2023 Q1 | 744 Thousand EUR | -24.57% |
| 2023 Q4 | 400.48 Thousand EUR | -37.52% |
| 2023 FY | 2.56 Million EUR | -26.41% |
| 2023 Q2 | 780 Thousand EUR | 4.84% |
| 2022 Q3 | 851 Thousand EUR | -4.38% |
| 2022 FY | 3.48 Million EUR | 78.42% |
| 2022 Q4 | 986.37 Thousand EUR | 15.91% |
| 2022 Q2 | 890 Thousand EUR | 17.11% |
| 2022 Q1 | 760 Thousand EUR | 16.11% |
| 2021 Q1 | 278 Thousand EUR | 49.67% |
| 2021 Q3 | 475 Thousand EUR | -13.0% |
| 2021 Q4 | 654.54 Thousand EUR | 37.8% |
| 2021 Q2 | 546 Thousand EUR | 96.4% |
| 2021 FY | 1.95 Million EUR | 184.61% |
| 2020 FY | 686.74 Thousand EUR | 1298.87% |
| 2020 Q4 | 185.74 Thousand EUR | 16.82% |
| 2020 Q3 | 159 Thousand EUR | -16.75% |
| 2020 Q2 | 191 Thousand EUR | 27.33% |
| 2020 Q1 | 150 Thousand EUR | 205.54% |
| 2019 Q1 | 99 Thousand EUR | 0.0% |
| 2019 Q4 | 49.09 Thousand EUR | -9.09% |
| 2019 FY | 49.09 Thousand EUR | -79.11% |
| 2019 Q3 | 54 Thousand EUR | -3.57% |
| 2019 Q2 | 56 Thousand EUR | -43.43% |
| 2018 FY | 235 Thousand EUR | 261.54% |
| 2017 FY | 65 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Biohit Oyj | 13.07 Million EUR | 80.373% |
| Herantis Pharma Oyj | - EUR | -Infinity% |